Overview

Clinical Trial Comparing the Pharmacological Effects of EP395 With Placebo in Healthy Adults

Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This study aims to assess the effect of EP395 against an induced inflammation of the lung. In addition, further data about the safety and tolerability of EP395 will be collected. To investigate the efficacy of EP395 at the end of the treatment with EP395 or placebo (dummy), all participants will inhale a lipopolysaccharide (a molecule composed of sugar and fat) that artificially induces an acute inflammation of the airways. It is assumed that participants who received EP395 will show less inflammation of the airways than participants who received placebo.
Phase:
Phase 1
Details
Lead Sponsor:
EpiEndo Pharmaceuticals
Collaborator:
FGK Clinical Research GmbH